(Q24245352)

2

0 references

Linda McIntyre

3

0 references

Pamela Royle

4

0 references

Jonathan J Shepherd

5

0 references

Sian Thomas

Cochrane Database of Systematic Reviews

6

0 references

publication date

18 April 2007

0 references

published in

0 references

cites work

Effects of nateglinide on myocardial microvascular reactivity in Type 2 diabetes mellitus--a randomized study using positron emission tomography

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Clinical pharmacokinetics and pharmacodynamics of repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Repaglinide acutely amplifies pulsatile insulin secretion by augmentation of burst mass with no effect on burst frequency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Plasma glucose levels throughout the day and HbA(1c) interrelationships in type 2 diabetes: implications for treatment and monitoring of metabolic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

A Coefficient of Agreement for Nominal Scales

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Pharmacologic therapy for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Insulinotropic meglitinide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Clinical significance, pathogenesis, and management of postprandial hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Quantifying heterogeneity in a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Meglitinide analogues in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Improvement of insulin resistance by a new insulin secretagogue, nateglinide--analysis based on the homeostasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

ABC of diabetes: Cardiovascular disease, hypertension, and lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004654.PUB2

Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus

21 January 2018

1 reference

12 December 2020

Repaglinide in combination therapy with metformin in Type 2 diabetes.

1 reference

12 December 2020

Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe

1 reference

12 December 2020

Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus

1 reference

12 December 2020

Insulin resistance and impaired glucose tolerance

1 reference

12 December 2020

Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study

1 reference

12 December 2020

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

12 December 2020

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

12 December 2020